Vera Therapeutics (Nasdaq:VERA) - Aandelenkoers, Nieuws & Analyse

VERA Overzicht aandelen

Vera Therapeutics, Inc., een biotechnologiebedrijf in een klinische fase, richt zich op de ontwikkeling en commercialisering van behandelingen voor patiënten met ernstige immunologische ziekten.

Over het bedrijf

VERA fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	0/6
Prestaties in het verleden	0/6
Financiële gezondheid	5/6
Dividenden	0/6

Beloningen

Verhandeld tegen 81.8% onder onze schatting van de reële waarde

Risicoanalyse

Heeft een omzet van minder dan 1 miljoen USD ( $0 )

Momenteel verlieslatend en er wordt niet verwacht dat dit de komende 3 jaar winstgevend zal worden.

Aandeelhouders zijn het afgelopen jaar verwaterd

Vera Therapeutics, Inc. Concurrenten

CG Oncology

NasdaqGS:CGON

US$2.5b

Arrowhead Pharmaceuticals

NasdaqGS:ARWR

US$2.6b

IDEAYA Biosciences

NasdaqGS:IDYA

US$2.6b

Twist Bioscience

NasdaqGS:TWST

US$2.5b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Vera Therapeutics
Historische aandelenkoersen
Huidige aandelenkoers	US$47.94
52 Week Hoogtepunt	US$50.78
52 Week Laag	US$10.50
Bèta	1.0
11 maand verandering	19.82%
3 maanden verandering	33.72%
1 Jaar Verandering	316.15%
33 jaar verandering	103.74%
5 jaar verandering	n/a
Verandering sinds IPO	316.87%

Recent nieuws en updates

Is Vera Therapeutics (NASDAQ:VERA) A Risky Investment?

Oct 07

Vera: Potential First Of Atacicept As A B-Cell Modulator For IgAN Patients

Oct 04

Recent updates

Companies Like Vera Therapeutics (NASDAQ:VERA) Are In A Position To Invest In Growth

Feb 16

Vera: Biotech With 3 Mid-Stage Programs With Potential For Success

Jan 19

Vera Therapeutics: Surprising Pivot To A Kidney Disease Drug Looks Like A Long Shot

Jan 07

We Think Vera Therapeutics (NASDAQ:VERA) Can Afford To Drive Business Growth

Oct 25

Vera Therapeutics soars 16% on three new favorable view from analysts

Jun 08

Rendement voor aandeelhouders

	VERA	US Biotechs	US Markt
7D	18.0%	1.6%	2.3%
1Y	316.1%	23.6%	35.1%

Rendement versus industrie: VERA overtrof de US Biotechs industrie, die het afgelopen jaar een rendement 23.6 % opleverde.

Rendement versus markt: VERA overtrof de US markt, die het afgelopen jaar een rendement opleverde van 35.1 %.

Prijsvolatiliteit

Is VERA's price volatile compared to industry and market?
VERA volatility
VERA Average Weekly Movement	8.5%
Biotechs Industry Average Movement	9.5%
Market Average Movement	6.2%
10% most volatile stocks in US Market	15.0%
10% least volatile stocks in US Market	2.9%

Stabiele aandelenkoers: VERA heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 9% ) van VERA is het afgelopen jaar stabiel geweest.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2016	72	Marshall Fordyce	veratx.com

Vera Therapeutics, Inc., een biotechnologiebedrijf in een klinische fase, richt zich op de ontwikkeling en commercialisering van behandelingen voor patiënten met ernstige immunologische ziekten. De belangrijkste productkandidaat is atacicept, een fusie-eiwit dat zelf wordt toegediend als onderhuidse injectie en dat zich in Fase III van de klinische studie bevindt voor patiënten met immunoglobuline A nefropathie; en voor de behandeling van lupus nefritis dat zich in Fase II van de klinische studie bevindt. Het ontwikkelt ook MAU868, een humaan monoklonaal antilichaam voor de behandeling van BK-viremie-infecties.

Vera Therapeutics, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Vera Therapeutics zich tot de beurswaarde?
VERA fundamentele statistieken
Marktkapitalisatie	US$2.62b
Inkomsten(TTM)	-US$107.85m
Inkomsten(TTM)	n/a

0.0x

P/S-verhouding

-24.4x

Koers/Winstverhouding

Is VERA overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
VERA resultatenrekening (TTM)
Inkomsten	US$0
Kosten van inkomsten	US$0
Brutowinst	US$0
Overige uitgaven	US$107.85m
Inkomsten	-US$107.85m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-1.97
Brutomarge	0.00%
Nettowinstmarge	0.00%
Schuld/Eigen Vermogen Verhouding	15.3%

Hoe presteerde VERA op de lange termijn?

Bekijk historische prestaties en vergelijking

VERA Overzicht aandelen

Beloningen

Risicoanalyse

Vera Therapeutics, Inc. Concurrenten

NasdaqGS:CGON

US$2.5b

NasdaqGS:ARWR

US$2.6b

NasdaqGS:IDYA

US$2.6b

NasdaqGS:TWST

US$2.5b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Vera Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $300.000036 million.

Vera Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $300 million.

Vera Therapeutics, Inc. Announces 96-week eGFR Stabilization in ORIGIN Phase 2b Study of Atacicept in IgAN at the American Society of Nephrology Kidney Week 2024

Is Vera Therapeutics (NASDAQ:VERA) A Risky Investment?

Vera: Potential First Of Atacicept As A B-Cell Modulator For IgAN Patients

Vera Therapeutics, Inc. Announces Expanded Atacicept Development Program in Multiple Autoimmune Kidney Diseases

Recent updates

Vera Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $300.000036 million.

Vera Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $300 million.

Vera Therapeutics, Inc. Announces 96-week eGFR Stabilization in ORIGIN Phase 2b Study of Atacicept in IgAN at the American Society of Nephrology Kidney Week 2024

Is Vera Therapeutics (NASDAQ:VERA) A Risky Investment?

Vera: Potential First Of Atacicept As A B-Cell Modulator For IgAN Patients

Vera Therapeutics, Inc. Announces Expanded Atacicept Development Program in Multiple Autoimmune Kidney Diseases

Vera Therapeutics' Atacicept: A Potential Game-Changer In IgA Nephropathy

Is Vera Therapeutics (NASDAQ:VERA) Using Debt In A Risky Way?

Vera Therapeutics, Inc.(NasdaqGM:VERA) dropped from Russell 3000E Value Index

Vera Therapeutics, Inc. Announces Appointment of David L. Johnson as Chief Operating Officer

Vera Therapeutics, Inc. Appoints Christy Oliger to the Board

Vera Therapeutics, Inc. Presents 72-Week eGFR Stabilization and Rapid Hematuria Improvement in Phase 2b ORIGIN Study of Atacicept in IgAN at the 61st European Renal Association Congress

Insider exercised options and sold US$1.0m worth of stock

Insider recently sold US$229k worth of stock

Price target increased by 17% to US$55.80

Chief Financial Officer recently sold US$735k worth of stock

Chief Financial Officer notifies of intention to sell stock

Vera Therapeutics, Inc., Annual General Meeting, May 15, 2024

Vera Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $250.000027 million.

Vera Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $250.000027 million.

Vera Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $200 million.

Price target increased by 36% to US$32.11

New minor risk - Share price stability

Vera Therapeutics: Soaring On IgAN Data, But Full Approval A Distant Prospect

Vera Therapeutics, Inc. Presents Positive 72-Week Data Showing eGFR Stabilization in the Phase 2b Origin Clinical Trial Ole in IgA Nephropathy

Vera Therapeutics, Inc. Announces Executive Changes

New minor risk - Share price stability

Price target increased by 12% to US$22.14

New major risk - Revenue and earnings growth

Price target increased by 16% to US$18.50

Price target increased by 10% to US$16.00

Price target decreased by 10% to US$14.50

New minor risk - Share price stability

Vera Therapeutics Appoints Kerry Cooper, M.D., as Senior Vice President of Medical Affairs

Price target decreased by 18% to US$15.67

Chief Financial Officer recently bought US$100k worth of stock

Vera Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $100.000005 million.

Vera Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $100.000005 million.

Vera Therapeutics, Inc. Releases 36 Week Interim Analysis of Phase 2b Clinical Trial of Atacicept for the Treatment of IgA Nephropathy

Vera Therapeutics, Inc. Hosting A Key Opinion Leader Webinar on Atacicept for the Treatment Iga Nephropathy (Igan)

Price target decreased to US$19.17

Vera Therapeutics, Inc. Announces Positive Topline Results of Phase 2b ORIGIN Clinical Trial of Atacicept for the Treatment of IgA Nephropathy

Chief Development Officer exercised options and sold US$148k worth of stock

Founder exercised options to buy US$1.1m worth of stock.

High number of new directors

Chief Development Officer exercised options and sold US$95k worth of stock

Founder exercised options and sold US$576k worth of stock

Chief Development Officer exercised options and sold US$186k worth of stock

Founder exercised options and sold US$622k worth of stock

Vera Therapeutics: Under The Radar IgAN Player Has Much To Prove

Founder exercised options and sold US$354k worth of stock

Vera Therapeutics GAAP EPS of -$0.55 beats by $0.17

Vera Therapeutics Completes Patient Enrollment in Phase 2B Origin Clinical Trial of Atacicept for the Treatment of Iga Nephropathy

Chief Financial Officer recently bought US$68k worth of stock

Vera Therapeutics, Inc. Reports Positive Interim Phase 2 Data Showing MAU868 Has Significant BK Antiviral Activity in Kidney Transplant Patients

High number of new directors

Vera Therapeutics Announces Two Oral Presentations at the 59th European Renal Association – European Dialysis and Transplant Association Congress Featuring New Clinical Data on Atacicept in IgA Nephropathy and in Systemic Lupus Erythematosus

High number of new directors

Vera Therapeutics, Inc., Annual General Meeting, May 24, 2022